Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.68 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | RBP4 | P02753 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22668886 | 0.85 | EPHX2 (0.73) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL1375425 | 0.84 | EPHX2 (0.68) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL22669112 | 0.83 | EPHX2 (0.71) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL1366662 | 0.82 | EPHX2 (0.69) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL3095680 | 0.82 | HSD11B1 (0.76) | EPHX2HSD11B1GAARBP4TRPV1 | |
| SCHEMBL4841943 | 0.81 | HSD11B1 (0.63) | EPHX2HSD11B1GAARBP4TRPV1 | |
| SCHEMBL6988200 | 0.81 | HSD11B1 (0.70) | EPHX2HSD11B1GAARBP4HSD17B10 | |
| SCHEMBL233710 | 0.81 | EPHX2 (1.00) | EPHX2HSD11B1GAAMAPTTSHR | |
| SCHEMBL30582915 | 0.81 | EPHX2 (0.68) | EPHX2HSD11B1GAARBP4MAPT | |
| SCHEMBL14507960 | 0.80 | HRH3 (0.65) | EPHX2HSD11B1GAARBP4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | EPHX2 2047/4885HSD11B1 2706/4885GAA 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.